Cellular localization of interleukin-5 expression in rectal carcinoma with eosinophilia

Human Pathology

Volumn 29, Issue 9, 1998, Pages 1024-1028

  Tajima, Katsushi ^a   Yamakawa, Mitsunori ^b   Inaba, Yukio ^b   Katagiri, Tadashi ^b   Sasaki, Hideo ^b  

^a YAMAGATA UNIVERSITY   (Japan)

^b NONE

Author keywords

Apoptosis; Eosinophilia; Interleukin; Rectal carcinoma

Indexed keywords

INTERLEUKIN 5;

AGED; APOPTOSIS; ARTICLE; CASE REPORT; CELL MIGRATION; CELL VIABILITY; CELLULAR DISTRIBUTION; DEGRANULATION; EOSINOPHILIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PROTEIN EXPRESSION; RECTUM CARCINOMA;

EID: 0031715568     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90212-X     Document Type: Article

References (23)

1. Stefanini M, Claustro JC, Motos RA, et al: Blood and bone marrow eosinophilia in malignant tumors. Cancer 68:543-548, 1991
2. Iwasaki K, Torisu M, Fujimura T: Malignant tumor and eosinophils; Prognostic significance in gastric cancer. Cancer 58:1321-1327, 1986
3. Pretlow TP, Keith EF, Cryar AK, et al: Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 43:2997-3000, 1983
4. Gleich GJ, Frigas E, Loegering DA, et al: Cytotoxic properties of the eosinophil major basic protein. J Immunol 123:2925-2927, 1979
5. Fermand JP, Mitjavila MT, Le Couedic JP, et al: Role of granulocyte-macrophage colony-stimulating factor, Interleukin-3 and Interleukin-5 in the eosinophilia associated with T cell lymphoma. Br J Haematol 83:359-364, 1993
6. Sanderson CJ: Interleukin-5, eosinophils, and disease. Blood 79:3101-3109, 1992
7. Dent LA, Strath M, Mellor AL, et al: Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 172:1425-1431, 1990
8. Weller PF: Seminars in medicine of the Beth Israel Hospital, Boston: The immunology of eosinophils. N Engl J Med 16:1110-1118, 1991
9. Martinez OM, Ascher NL, Ferrell L, et al: Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation 55:909-918, 1993
10. Hogan B, Costantini F, Lacy E: Manipulating the mouse embryo: A laboratory manual. Cold Spring Harbor, New York, Cold Spring Harbor Laboratory 1986, pp 228-242
11. Peters MS, Gleich GJ, Dunnette SL, et al: Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: A morphological basis of hypodense eosinophils. Blood 71:780-785, 1988
12. Owen WF, Rothenberg ME, Petersen J, et al: Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 170:343-348, 1989
13. Slungaard A, Ascensao J, Zanjani E, et al: Pulmonary carcinoma with eosinophilia: Demonstration of a tumor-derived eosinophilopoietic factor. N Engl J Med 309:778-781, 1983
14. Yamaguchi Y, Suda T, Suda J, et al: Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 309:778-781, 1988
15. Cogan E, Schandene L, Crusiaux A, et al: Brief report: Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 330:535-538, 1994
16. Plaut M, Pierce JH, Watson CJ, et al: Mast cell lines produce lymphokines in response to cross-linkage of Fc RI or to calcium ionophores. Nature 339:64-67, 1989
17. Hamid Q, Azzawi M, Ying S, et al: Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 87:1541-1546, 1991
18. Dubucquoi S, Janin A, Desreumaux P, et al: Evidence for eosinophil activated in eosinophilic cystitis. Eur Urol 25:254-258, 1994
19. Navarro-Roman L, Medeiros LJ, Kingman DW, et al: Malignant lymphomas of B-cell lineage with marked tissue eosinophilia: A report of five cases. Am J Surg Pathol 18:347-356, 1994
20. Arinaga S, Krimine N, Takamuku K, et al: Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C. Cancer Immunol Immunother 35:246-250, 1992
21. Huland E, Huland H: Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 118:463-467, 1992
22. Enokihara H, Kajitani H, Nagashima S, et al: Interleukin 5 activity in sera from patients with eosinophilia. Br J Haematol 75:458-462, 1990
23. Prin L, Plumas J, Gruart V, et al: Elevated serum levels of soluble interleukin-2 receptor: A marker of disease activity in the hypereosinophilic syndrome. Blood 78:2626-2632, 1991